Article
Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicity.
The pharmacogenomics journal - 1 Dec 2007
Fujiwara T, Ikeda M, Esumi K, Fujita T D, Kono M, Tokushige H, Hatoyama T, Maeda T, Asai T, Ogawa T, Katsumata T, Sasaki S, Suzuki E, Suzuki M, Hino F, Fujita T K, Zaima H, Shimada M, Sugawara T, Tsuzuki Y, Hashimoto Y, Hishigaki H, Horimoto S, Miyajima N, Yamamoto T, Imagawa K, Sesoko S, Fujisawa Y
Abstract excerpt
Aspirin prevents the production of thromboxane A2 (TXA2) by irreversibly inhibiting platelet cyclooxygenase, exhibiting antiplatelet actions. This agent has been reported to prevent relapse in patients with ischemic heart disease or cerebral infarction via this action mechanism. However, there are individual differences in this action, and aspirin is not effective in some patients, which is referred to as...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.